Q1 FY27 saw 8% revenue growth to $105.4B and 20% adjusted EPS growth to $9.93, with strong performance in Oncology & Multispecialty and Prescription Technology Solutions. FY27 adjusted EPS guidance was raised to $44.20–$45.00, and $2.5B in share repurchases were completed.Original document: McKesso…
Healthcare distributor and services company McKesson NYSE:MCKwill be reporting results this Wednesday afternoon. Here’s what to expect.McKesson missed analysts’ revenue expectations last quarter, reporting revenues of $96.3 billion, up 6% year on year. It was a slower quarter for the company, with…
McKesson Corporation MCK is scheduled to report first-quarter fiscal 2027 results on Aug 5, after market close.The Zacks Consensus Estimate for sales is pegged at $104.25 billion, implying 6.6% year-over-year growth. The bottom line estimate is pinned at $9.46, suggesting growth of 14.5%.The EPS es…
McKesson Corporation (NYSE:MCK) boosted its quarterly dividend 15% to $0.94 (annualized $3.76) payable Oct. 1 to Sept. 1 record holders while Citigroup reiterated a Buy and lifted its price target to $1,000 from $945, signaling stronger valuation momentum despite a modest implied yield near 0.45%.P…
